Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 16, 2025Deleted Journal

CAR-T-Zell-Therapie bei der akuten lymphoblastischen Leukämie

View Full Paper
Ask AI
Bookmark
Share

Authors

MCManik ChatterjeeRBRalf C. Bargou

Discussion

Loading...

Member takes

Overview

Pivotal trials demonstrate CAR-T cell therapy improves outcomes in relapsed B-precursor ALL, highlighting its clinical significance.

Key Points

  • CAR-T cell therapy has revolutionized treatment for relapsed and refractory B-precursor acute lymphoblastic leukemia (ALL).
  • Clinical trials show that CAR-T cell therapy significantly improves patient prognosis after chemotherapy.
  • The therapy's side effects require careful clinical management to ensure patient safety during treatment.
  • Emerging CAR-T cell approaches targeting CD5 and CD7 indicate ongoing advancements in treating T-precursor ALL.

Cite This Study

Chatterjee et al. (2025) studied this question.

synapsesocial.com/papers/689a02c3e6551bb0af8cc99ehttps://doi.org/10.1007/s00108-025-01949-7
View Full Paper
Ask AI
Bookmark
Share